AstraZeneca (AZN) Reels from China Investigation and Investor Suit– Hagens Berman
By Hagens Berman Sobol Shapiro LLP | Published on 2025-01-03T14:11:00Z
Description
SAN FRANCISCO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- AstraZeneca (NASDAQ: AZN), the Anglo-Swedish pharmaceutical giant, has seen its stock price tumble 15 percent over the past six months, buffeted by a series of unsettling reports emanating from China. A widenin…
Full Content
SAN FRANCISCO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- AstraZeneca (NASDAQ: AZN), the Anglo-Swedish pharmaceutical giant, has seen its stock price tumble 15 percent over the past six months, buffeted by a … [+5197 chars]
Insights
This article highlights recent developments in the world of news. Stay informed with the latest updates on global events, technology, politics, entertainment, and more. Dive into the details to get a comprehensive understanding of this topic.
Comments
Post a Comment